October 26 Earnings: Gilead - Flying the Kite

Gilead's core product pipeline, including recent FDA approval is set to soar as key drugs and generics are continuing to outperform.
The company's recent acquisition of KITE Pharma came at the perfect moment with KITE being granted a key drug approval by the FDA.
Gilead's recent cost cutting efforts and R&D focus are to further push growth prospect and boost overall FY guidance.

Generic competition will continue to weigh, however, and limit some blockbuster drug expansion.

I'm starting Gilead with a $90 PT for an extended post-earnings move.
A S/L at $75 around recent area is advised.


Home Stock Screener Forex Screener Crypto Screener Economic Calendar About Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Private Messages Chat Sign Out